Alignment Healthcare (ALHC) has been under sustained selling pressure over the past month after analyst downgrades from Barclays and Raymond James, setting the backdrop as the company heads into a high profile healthcare conference.

That selling pressure shows up clearly in the numbers, with a 30 day share price return of down 17.65% and a year to date share price return of down 25.47%. However, the three year total shareholder return of 116.52% remains very strong by comparison and hints at a stock where short term momentum has faded while the longer term picture is still constructive.

If the recent volatility around Alignment Healthcare has you reviewing the sector, it can be useful to compare it with other Medicare focused technology players using our curated list of 40 healthcare AI stocks

So with Alignment Healthcare trading well below the average analyst price target but coming off a sharp pullback, is this a case of investors getting a bargain, or is the market already discounting the company’s future growth?

Most Popular Narrative: 39.5% Undervalued

Analysts following Alignment Healthcare currently see fair value at $24.92 per share versus the last close of $15.07, framing a wide gap that hinges on how the Medicare Advantage story plays out over the next several years.

Alignment's robust, technology-enabled care model and investments in administrative automation, workflow standardization, and digital health platforms position the company to significantly lower SG&A expenses and improve scalability, likely powering both margin expansion and earnings growth over the next several years.

Curious what sits behind that confidence in margins and earnings. The narrative leans heavily on rapid membership growth, rising profitability, and a richer earnings multiple. The exact mix of growth, margin uplift, and discount rate assumptions might surprise you.

Result: Fair Value of $24.92 (UNDERVALUED)

However, that upbeat story can unravel quickly if Medicare Advantage reimbursement tightens, or if rising competition pushes up member acquisition costs and squeezes margins.

Next Steps

With sentiment clearly split between risks and rewards, this is the moment to move quickly, review the underlying data, and weigh the 5 key rewards and 1 important warning sign

Looking for more investment ideas?

If you stop here, you could miss stocks that better fit your goals, so take a few minutes to scan fresh opportunities with the Simply Wall Street Screener.

• Target long term compounding potential by reviewing steady performers through the 65 resilient stocks with low risk scores that may suit investors who prioritize resilience.
• Chase value opportunities by checking companies flagged in the 47 high quality undervalued stocks where pricing and fundamentals may not yet match up.
• Spot early standouts by scanning the screener containing 22 high quality undiscovered gems before wider attention potentially arrives.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.